Salirasib

N/A

Report date: 2025/05/29 16:54:25
NME

Base Information

Drug NameSalirasib
Drug Alias Namesalirasibum沙立拉司S-Farnesylthiosalicyclic acid沙利雷塞Transfarnesylthiosalicyclic acid +[8] 
ClassificationSmall molecules
Mechanisms of ActionmTOR Complex 2 inhibitorsGTPase Ras inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors +[4] 
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2GTPase Ras +[4] 
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesOno Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterConcordia Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungLeukemia

Other Information

ATC CodeN/A
Related LinksKEGG